Bioorganic & Medicinal Chemistry Letters 2006-11-01

A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors.

Namal C Warshakoon, Shengde Wu, Angelique Boyer, Richard Kawamoto, Justin Sheville, Sean Renock, Kevin Xu, Matthew Pokross, Artem G Evdokimov, Richard Walter, Marlene Mekel

Index: Bioorg. Med. Chem. Lett. 16(21) , 5598-601, (2006)

Full Text: HTML

Abstract

Utilizing modeling information from a recently resolved structure of human HIF-1alpha prolyl hydroxylase (EGLN1) and structure-based design, a novel series of imidazo[1,2-a]pyridine derivatives was prepared. The activity of these compounds was determined in a human EGLN1 assay and a limited SAR was developed.

Related Compounds

Related Articles:

Conversion of pyridine to imidazo[1,2-a]pyridines by copper-catalyzed aerobic dehydrogenative cyclization with oxime esters.

2013-12-20

[Org. Lett. 15(24) , 6254-7, (2013)]

One-pot three-component synthesis of 3-nitro-2-arylimidazo[1,2-a]pyridine derivatives using air as an oxidant.

2012-09-01

[Chem. Asian J. 7(9) , 2028-31, (2012)]

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.

2007-01-01

[Bioorg. Med. Chem. 15(1) , 403-12, (2007)]

Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.

2011-05-01

[Eur. J. Med. Chem. 46 , 1874, (2011)]

Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors

2012-12-15

[Bioorg. Med. Chem. Lett. 22(24) , 7326-9, (2012)]

More Articles...